Mutual of America Capital Management LLC lowered its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,438 shares of the biopharmaceutical company’s stock after selling 557 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $3,338,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ALXN. Guardian Life Insurance Co. of America lifted its stake in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 6 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at $111,000. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $111,000. Huntington National Bank lifted its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the period. Finally, Penserra Capital Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. 94.17% of the stock is currently owned by institutional investors.

In other news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders have sold 17,070 shares of company stock worth $2,416,869 in the last quarter. Company insiders own 4.35% of the company’s stock.

A number of research analysts have recently weighed in on the company. Leerink Swann reissued a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. Deutsche Bank AG reissued a “buy” rating and issued a $158.00 price target (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $157.21.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/mutual-of-america-capital-management-llc-has-3-34-million-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 139.45 on Thursday. The company has a market cap of $31.12 billion, a PE ratio of 60.47 and a beta of 1.40. The firm’s 50-day moving average price is $139.14 and its 200-day moving average price is $124.77. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the prior year, the business earned $1.13 earnings per share. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.